Key Takeaways
- Altria (MO) reached a fresh 52-week peak of $76.17, closing near $76.48
- First-quarter earnings per share of $1.32 surpassed analyst forecasts of $1.25; revenue of $4.76B exceeded projections by $180M
- Company issued full-year 2026 EPS outlook ranging from $5.56 to $5.72
- Current quarterly dividend stands at $1.06 per share, yielding approximately 5.5%
- Wall Street consensus remains “Hold” with mean price target at $70.78
Shares of MO climbed to an unprecedented 52-week peak this Tuesday, reaching $76.17 intraday before closing near $76.48 — marking a significant jump from the prior session’s close of $72.89. The tobacco giant has delivered a 30.45% gain since the start of the year and posted a 32.55% return over the trailing twelve months.
This upward momentum follows an impressive first-quarter performance that exceeded Wall Street’s expectations. The company reported earnings per share of $1.32, topping consensus forecasts of $1.25. Total revenue reached $4.76 billion, reflecting a 5.3% year-over-year increase and beating analyst projections of $4.58 billion.
Looking ahead to fiscal 2026, management has established an earnings per share guidance range of $5.56 to $5.72. Wall Street analysts are currently modeling $5.70 for the full year.
High-Yield Dividend Remains Key Attraction
Altria distributed a $1.06 per share quarterly dividend on July 10, translating to an annualized distribution of $4.24 and yielding approximately 5.5%. The corporation has sustained uninterrupted dividend payments for 56 consecutive years.
While the payout ratio stands elevated at 88.7%, the company’s reliable income stream continues drawing yield-seeking shareholders.
Recent SEC filings revealed that two board members reduced their holdings in May. Director Debra J. Kelly divested 5,790 shares at $72.25 per share, trimming her stake by 7.27%. Ellen R. Strahlman sold 2,000 shares at $72.56, representing a 7.38% position decrease. Both sales were properly disclosed to regulators.
Institutional ownership accounts for 57.41% of outstanding shares. Multiple investment firms have expanded their positions in recent reporting periods, with Bernardo Wealth Planning boosting its holdings by 4.6% during the second quarter.
Wall Street Maintains Cautious Stance
The overall analyst consensus for MO stands at “Hold,” with a mean price objective of $70.78 — notably below current trading levels.
UBS maintains a Buy recommendation alongside a $79 price target. Bank of America revised its projections following advantageous regulatory developments in the tobacco industry during Q2. BTIG launched coverage in July with a Neutral stance.
Citigroup elevated its target from $65 to $70 while maintaining a Neutral rating. Morgan Stanley maintains a $71 objective. Jefferies holds an Underperform rating with a $60 target. Across the 12 analysts tracking the stock, five recommend buying, five suggest holding, and two advise selling.
The FDA recently unveiled a proposed regulation mandating foreign tobacco producers to register their manufacturing facilities. Industry observers interpreted this proposal as favorable for domestic operators like Altria.
Data from Bank of America indicates oral tobacco products demonstrated growth momentum through late May, while traditional cigarette and vaping product sales experienced declines.
MO currently commands a market capitalization of $127.82 billion, trades at a price-to-earnings multiple of 16.01, and exhibits a beta of 0.45. The stock’s 50-day moving average sits at $71.90, while its 200-day moving average stands at $67.95.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
